This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
Freelance translator and/or interpreter, Verified site user
Data security
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Affiliations
This person is not affiliated with any business or Blue Board record at ProZ.com.
Services
Translation, Editing/proofreading
Expertise
Specializes in:
Medical (general)
Medical: Health Care
Also works in:
Certificates, Diplomas, Licenses, CVs
Tourism & Travel
Psychology
General / Conversation / Greetings / Letters
More
Less
Rates
Spanish to English - Rates: 0.05 - 0.09 EUR per word / 30 - 30 EUR per hour
Translation Volume: 1500 words Completed: Oct 2016 Languages: Spanish to English
medical documents
Medical (general)
No comment.
Translation Volume: 9591 words Completed: Jun 2015 Languages:
Spanish to English
Spanish to English Video transcriptions
Thank you for your good work, cooperation with you was very easy and the quality of the translation is very good.
I am looking forward to working again with you too, hopefully not with such tight schedule this time.
Medical: Health Care
No comment.
Translation Volume: 2798 words Completed: Nov 2011 Languages: Spanish to English
Educational conference material
Quality of contribution:
Good.<br>
Respect to deadlines:
Excellent.<br>
Communication:
Good.<br>
Overall satisfaction with the collaboration:
Excellent
International Org/Dev/Coop
No comment.
More
Less
Blue Board entries made by this user
2 entries
Access to Blue Board comments is restricted for non-members. Click the outsourcer name to view the Blue Board record and see options for gaining access to this information.
Spanish to English: Impacto del estado del hierro en la insuficiencia cardiaca General field: Medical Detailed field: Medical: Cardiology
Source text - Spanish Impacto del estado del hierro en la insuficiencia cardiaca.
Nuestros autores se plantearon evaluar el efecto del déficit de hierro y la anemia sobre los síntomas y la capacidad funcional en pacientes con insuficiencia cardiaca crónica. Y los resultados son sorprendentes.
El trabajo es un estudio transversal unicéntrico en el que se incluyeron 538 pacientes con insuficiencia cardiaca crónica en situación estable a los que se les realizó una prueba de marcha de 6 minutos y un estudio completo del metabolismo del hierro.
Los autores comprobaron que los pacientes con alteración del metabolismo del hierro caminaron una distancia más corta (285±101 m frente a 322±113 m, p=0,002) y tuvieron más síntomas durante la prueba (sobre todo fatiga 35% frente a 27%) en comparación con los pacientes con estudio de hierro normal.
En el análisis multivariado, la concentración del receptor de transferrina soluble y el índice de ferritina, que son marcadores asociados al estado del hierro, mostraron una asociación lineal, significativa e independiente con la capacidad de ejercicio submáxima. Sin embargo, los niveles de hemoglobina no se asociaron con la distancia recorrida en la prueba de marcha de 6 minutos.
Translation - English The effect that iron has in heart failure.
Our authors wanted to see what effect iron deficiency and anemia had on patients with chronic cardiac failure with respect to their symptoms and functional abilities .
The results were surprising.
The research is a single center cross sectional study that consists of 538 patients with chronic heart failure who were put in a stable situation where they were asked to do a 6 minute walk and under go a complete iron metabolism test.
The authors found that those patients with a change in the Iron metabolism walked a shorter distance(285+/- 101m compared to 322+/-113m, p=0.002) and showed signs of symptoms during the test (mainly fatigue 35% as opposed to 27%) compared to those patients who were showing normal Iron readings.
In the multivaried analysis, the receptor of the soluble transferrin and the ferritin index, that are the markers associated with the the state of Iron, showed a linear association that is significant and independent to the capacity of sub maximum force. However, the levels of haemoglobin were not associated with the distance travelled in the 6 minute walking test.
Spanish to English: Procedimientos Operativos estándar --Standard Operating Procedures(SOP) General field: Medical Detailed field: Medical (general)
Source text - Spanish Medicamentos Falsificados – Pautas para la formulación de medidas para combatir los medicamentos falsificados
• Debe diseñarse un POE escrito para los inspectores y ponerse a su disposición. El mencionado POE debe incluir al menos la siguiente información:
-como el producto bajo sospecha debe aislarse a fin de prevenir su distribución en otros lugares.
-el tamaño de las muestras requeridas para el objetivo de la prueba.
-la manera en la cual deben tomarse las muestras.
-el procedimiento de registro que se utilizara para registrar los detalles de las medidas adoptadas.
-los detalles que deben registrarse en el recibo expedido para el producto embargado o las muestras tomadas.
-el tipo de materiales que deben emplearse para sellar las muestras o para embargar o confiscar los productos bajo sospecha.
-los nombres, las direcciones y los números telefónicas de las personas que deben contactarse para informarles sobre las medidas adoptadas.
-las precauciones especiales que debe observar la persona que inicia el proceso de muestreo o de incautación con especial referencia a los procedimientos legales correctos que deben seguirse.
- el los casos en que correspondiese, la manera en la que el producto bajo sospecha debe destruirse.
• Cuando otras personas participen en la detección de productos farmacéuticos falsificados, estas deben operar de acuerdo con un POE apropiado. Cada vez que se sospeche sobre productos farmacéuticos falsificados se debe notificar inmediatamente a un inspector.
Translation - English Counterfeit drugs - Guidelines for the development of measures to combat counterfeit drugs.
• A written SOP must be designed for the inspectors and to be available to them. The mentioned SOP must include at least the following information:
- How the suspect product should be isolated with the goal of preventing its distribution to other places.
- The size of the samples seized for testing.
-The way in which the samples should be seized.
- The recording procedure that will be used to record the details of measures taken.
- The details that must be recorded in receipt issued for the seized or taken samples.
- The type of materials that should be used to seal the samples or to seize or confiscate the suspect products.
- The names, addresses and phone numbers of the people who should be contacted to inform them of the measures taken.
- The special precautions that the person who started the sampling should observe or the seizure procedure with special reference to the correct legal procedures that should be followed.
- in the cases where it applies to you, the way the suspect product should be destroyed.
• When other people participate in the detection of pharmaceutical counterfeit products, they should work in accordance with the appropriate SOP. Each time you suspect that a pharmaceutical product is counterfeit you must notify an inspector immediately.
Spanish to English: Medical Report General field: Medical Detailed field: Medical (general)
Source text - Spanish Informe medico
Dn. X…..
Fecha de Consulta: 13 Febrero 2002
ANAMNESIS
Paciente de 46 years of age, natural de Santiago de Compostela, residente en Albacete, con 2 hijos, diagnosticado recientemente de carcinoma epidermiode de cavidad oral, que acude a consulta para valoración.
Antecedentes Familiares
No se conoce
Antecedentes Patológicos.
Ha estado siempre sano. Fue operado en 1999 de adenoma pleomorfo de parótida derecha que media 3,2 x 2cm de diámetros, que ha estado controlado después de una parotidectomia superficial.
Ha sido fumador hasta hace un ano.
Enfermedad Actual
Hace más de 1 mes noto la aparición de un nódulo en región posterior de la cavidad oral del lado izquierdo, y que ha ido creciendo. Le duele un poco. Puede comer bien.
Se ha hecho un TAC que visualiza un nódulo de 1cm en región del paladar izquierdo. La biopsia ha demostrado carcinoma epidermoide.
Anamnesis por sistema y aparatos.
Vida active normal. Come y duerme bien.
Medicación:
No toma
Exploración física.
Alerta, colaborador. Karnofsky 100%. TA 120/60. Talla 182cm. Peso 102Kg.
Cabeza y cuello: pares craneales intactos.
Cavidad oral normal: Tumor ulcerado en pilar anterior de amígdala de 1,5cm, que se prolonga inferiormente en la pared de la faringe, pero no invade base de lengua, o trígono retromolar. No hay adenopatías cervicales, maxilares, o supraclaviculares. Tiroides normal.
Mamas y axilas libres.
Percusión ósea y flancos normal.
Auscultación cardiopulmonar: ritmo sinusal sin soplos. No hay ruidos respiratorios sobreañadidos.
Abdomen: blando, depresible, sin organomegalias.
Regiones inguinales: libres.
Recomendaciones:
Se recomienda quicio/radioterapia simultánea de inducción, y plantear posteriormente cirugía de rescate.
La quimioterapia que nosotros propondríamos seria CISPPLANTINO, 40 mg/m2,
IRINOTECAN, 100mg/m2, TAXOL, 60mg/m2, repetido cada 2 semanas.
Se remite el paciente al Dr. Y para organizar el tratamiento de quimioterapia en su propio centro, y radioterapia en la clínica Universitaria.
Se deja consulta abierta.
Translation - English Medical report
Mr .X
Consultation date: 13 February 2002
Medical History
46 year old patient from Santiago de Compostela, resident of Albacete, with 2 sons, recently diagnosed with epidermoid carcinoma in the oral cavity, and went for a check-up.
Family History
Unknown
Past medical history
He has always been healthy.
The right pleomorfo adenoma that measured 3.2 x 2cm in diameter was operated on in 1999, and had been controlled after a superficial parotidictomy
He has been smoker until a year ago.
Current condition
Over a month ago I noticed a lump in the back of the left oral cavity, and its has been growing.
It hurts him a bit.
He is able to eat.
A CAT scan has been done that shows a 1cm lump in the left palate. The biopsy has shown epidermoid carcinoma.
History by systems.
Normal active life.
Has a healthy appetite and sleeps well.
Medication
He doesn’t take medication
Physical examination
Alert, helpful. Karnofsky 100%. BP 120/60. Height 182cm. Weight 102Kg.
Head and neck: cranial nerves intact
Oral cavity normal: Ulcerated tumor in the front palate of 1.5cm, that extends away from pharynx wall, but has not entered the base of the tongue or the retromolar trigone There are no maxillary, supraclavicular lymphadenopathy. Normal thyroid.
Breasts and armpits disease free.
Flanks and bony percussions are normal
Cardiopulmonary auscultation: sinus rhythm without murmurs There were no additional sounds
Abdomen: soft, not tender, without organomegaly
Inguinal canal: unobstructed
Recommendations:
Simultaneous chemo/radiation therapy induction, and have a follow up surgery
The chemotherapy we would propose would be CISPLATIN, 40 mg/m2,
IRINOTECAN, 100mg/m2, TAXOL, 60mg/m2, repeated every 2 weeks.
The patient was referred to the Dr. Y to organize the treatment of chemotherapy in his centre, and radiation therapy in the University clinic.
To this end we leave the consultation open.
Spanish to English: Alzheimer | A new therapy with promising results General field: Medical Detailed field: Medical: Health Care
Source text - Spanish Alzheimer | Una nueva terapia con resultados prometedores
Los científicos del Instituto Karolinska han evaluado una nueva terapia para la Enfermedad de Alzheimer en la que los pacientes reciben un implante que estimula el crecimiento de un determinado tipo de célula nerviosa. Los resultados, publicados en la revista científica de Alzheimer y la demencia, sugieren que la introducción de un factor de crecimiento nervioso puede prevenir la degradación neuronal en los pacientes de Alzheimer.
Los pacientes con la enfermedad de Alzheimer sufren una degradación selectiva y temprana de las llamadas células nerviosas colinérgicas, que requieren un factor de crecimiento nervioso específico (NGF) – esencialmente un grupo de proteínas necesarias para el crecimiento celular y la supervivencia – a la función. Como los niveles de NGF disminuyen, las células nerviosas colinérgicas comienzan a degradarse y el estado del paciente se deteriora lentamente.
En un intento por frenar la descomposición de las células nerviosas colinérgicas, los investigadores en el Centro de Instituto Karolinska de Investigación de Alzheimer y sus colegas de la clínica de neurocirugía del Hospital Universitario Karolinska y la empresa danesa de biotecnología NsGene introdujeron NGF directamente en el cerebro de pacientes con Alzheimer. Para ello, usaron NGF productoras de cápsulas celulares, colocarlos en el cerebro anterior basal donde las células colinérgicas residen mediante cirugía estereotáctica precisión. Hay las cápsulas, que pueden ser fácilmente eliminadas, liberan NGF a las células que rodean a fin de evitar su degradación.
El estudio ahora publicado en el Alzheimer y la demencia se basa en datos de seis pacientes de Alzheimer. Para medir si la liberación de NGF tuvo ningún efecto sobre las células nerviosas colinérgicas, los investigadores analizaron la presencia de marcadores específicos de funcionamiento de las células colinérgicas. Este sistema de célula se comunica utilizando la acetilcolina, que a su vez produce una llamada enzima ChAT (pronunciado Cat) que se encuentra tanto dentro como fuera de las células. Por ello, el equipo desarrolló un método que les permita medir chat en el líquido cefalorraquídeo, por primera vez.
“Nuestros resultados muestran que cuando los pacientes recibieron NGF, hubo un aumento significativo en el chat en el LCR,” dice el Dr. Taher Darreh-Shori, uno de los investigadores involucrados en el estudio. “Los pacientes que mostraron este aumento fueron también los que respondieron mejor al tratamiento. Nuestra TEP también mostró un aumento en la actividad de las células colinérgicas y el metabolismo en el cerebro.”
Además, los investigadores fueron capaces de detectar un retraso del deterioro de la memoria a través del tiempo en comparación con los pacientes no tratados. Mientras todo esto sugiere que la funcionalidad colinérgica mejoró en los pacientes de Alzheimer que habían recibido terapia de NGF, el equipo añade la advertencia de que las conclusiones de largo alcance no deben extraerse de los resultados:
“Los resultados son prometedores, pero deben ser tratados con cautela, ya que sólo unos pocos pacientes participaron en el estudio”, dice el investigador principal profesora María Eriksdotter. “Así que nuestros resultados tendrán que ser fundamentada en un estudio controlado más grande, utilizando más pacientes.”
Translation - English Alzheimer | A new therapy with promising results
The scientists of the Karolinska Institute have evaluated a new therapy for Alzheimers Disease in which the patients receive implants that stimulate the growth of a certain type of nerve cell. The results, published in the scientific magazine of Alzheimers and dementia, suggest that the introduction of a factor of nerve growth can prevent neuronal degradation in the patients with Alzheimers.
The patients with the Alzheimers Disease suffer a selective and early degradation of the so called cholinergic nerve cells, that essentially require a specific nerve growth factor (NGF) - a necessary protein group for the cellular growth and survival. As the NGF levels diminish, the cholinergic nerve cells begin to degrade and the state of the patient deteriorates slowly.
In an attempt to slow down the decomposition of the cholinergic nerve cells, the investigators in Institute Karolinska Center for the investigation of Alzheimers and its colleagues of the clinic of neurosurgery of the University Hospital Karolinska and the Danish biotechnology company of NsGene introduced NGF directly in the brain of patients with Alzheimer. For this, they used NGF producing cell tablets , they are placed them in the basal forebrain where the cholinergic cells reside by means of precision stereotactic surgery . There are capsules that can easily be eliminated, they release NGF to the cells that surround them, in order to avoid their degradation.
The study now published in the Alzheimers and the dementia is based on data of six patients with Alzheimers. In order to measure if the NGF liberated had no effect on the cholinergic nerve cells, the investigators analysed the presence of specific markers in the performance of the cholinergic cells. This system of cells communicates by using the acetylcholine, that produces at the same time an enzyme call ChAT (pronouncing Cat) that is found as much inside as outside the cells. For that reason, the team developed a method that allows them to measure chat in the spinal fluid, for the first time.
“Our results show that when the patients received NGF, there was a significant increase in chat in the LCR,” says the Dr. Taher Darreh-Shori, one of the researchers involved in the study. “The patients who showed this increase were also those that responded better to the treatment. Our TPP also showed to an increase in the activity of the cholinergics cells and the metabolism in the brain.”
In addition, the investigators were able to detect a delay in the deterioration of the memory through time in comparison with patients who were not treated. While all this suggests that the cholinergics functionality improved in the patients with Alzheimers who had received NGF therapy, the team added the warning of which the conclusions in the long term must not have to be extracted from the results:
“The results are promising, but they must be dealt with caution, since just a few patient who participated in the study”, says to the main researcher professor Maria Eriksdotter. “So our results will have to be based on a controlled study greater, using more patients.”
Spanish to English: Alzheimer's Disease General field: Medical Detailed field: Medical: Health Care
Source text - Spanish La enfermedad de Alzheimer (EA) es la forma más común de demencia entre las personas mayores. La demencia es un trastorno cerebral que afecta gravemente la capacidad de una persona de llevar a cabo sus actividades cotidianas.
La EA comienza lentamente. Primero afecta las partes del cerebro que controlan el pensamiento, la memoria y el lenguaje. Las personas con EA pueden tener dificultades para recordar cosas que ocurrieron recientemente o los nombres de personas que conocen. Un problema relacionado, el deterioro cognitivo leve, causa más problemas de memoria que los normales en personas de la misma edad. Muchos, pero no toda la gente con deterioro cognitivo leve, desarrollarán Alzheimer. Con el tiempo, en el Alzheimer, los síntomas empeoran. Las personas pueden no reconocer a sus familiares o tener dificultades para hablar, leer o escribir. Pueden olvidar cómo cepillarse los dientes o peinarse el cabello. Más adelante, pueden volverse ansiosos o agresivos o deambular lejos de su casa. Finalmente, necesitan cuidados totales. Esto puede ser muy estresante para los familiares que deben encargarse de sus cuidados.
La EA suele comenzar después de los 60 años. El riesgo aumenta a medida que la persona envejece. El riesgo es mayor si hay personas en la familia que tuvieron la enfermedad.
Ningún tratamiento puede detener la enfermedad. Sin embargo, algunos fármacos pueden ayudar a impedir por un tiempo limitado que los síntomas empeoren.
Translation - English Alzheimer’s disease is the most common form of dementia in third generation people. Dementia is a brain disorder that seriously affects the capacity of a person to carry out its daily activities.
AD begins slowly. First it affects the parts of the brain that control thought, memory and speech. People with AD can have difficulties in remembering recent events or friends names. A related problem, mild cognitive deterioration, cause more memory problems than in normal people of the same age. Many, but not all people with mild cognitive deterioration will develop Alzheimer. With time, the symptoms of Alzheimer’s will get worse. These people can not recognize their relatives or have difficulties speaking, reading or writing. They can forget how to brush their teeth or to comb their hair. Later, they can become anxious or aggressive or to walk faraway from their house. Finally, they need total care. This can be very stressful for the family who are in charge of their care.
AD usually occurs in people of 60 years and over. The risk increases as the person gets older. The risk is greater if there are people in the family who have had the disease.
No treatment can stop the disease. However, some drugs can help to prevent the symptoms from getting worse for a limited time.
I am continually investing in translation to offer you a better service.
Languages have always been my passion, in particular the language of my second home, Spain, so I decided to become an interpreter/ translator and build a career doing something I love.
I attended the University of Northampton where I studied my DPSI (Diploma in Public Service Interpreting - Healthcare Pathway) for interpreting in 2012.
After my father passed away that same year, I had to spend some time working from the UK and Portugal where my parents live; As I could no longer work as an interpreter I started to work as a translator, and over the years I have worked successfully for multiple clients.
*****When sending me a request, please quote deadline in GMT time*******
This user has earned KudoZ points by helping other translators with PRO-level terms. Click point total(s) to see term translations provided.
Expertise 
